BioSpace

Roche cuts muscle-sparing obesity drug after mid-stage disappointment

Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.

作者 BioSpace

1 分钟阅读
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche cuts muscle-sparing obesity drug after mid-stage disappointment

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察